Why Asian API manufacturers underpin the supply

The global research-peptide market runs on active pharmaceutical ingredients (APIs) synthesised overwhelmingly in East Asia. The facilities sit in China, South Korea, and Taiwan, and they range from commercial-scale GMP plants to specialist GLP-1 workshops. Their output moves through distributors and research-chemical vendors before it reaches end buyers. Knowing that chain, and the independent testing setup that runs alongside it, helps researchers judge what they are buying.

Note: peptides sold by research-chemical vendors are labelled for research use only and are not approved for human consumption. Nothing here is medical, dosing, or purchasing advice.

The Asian API base

China holds the largest share of global peptide-API capacity. A few facilities stand out:

South Korea: Anygen (Gwangju) is reported to have been Korea's first peptide manufacturer to obtain GMP status for mass production, in 2011 per the company, serving both domestic pharma and export markets.

Taiwan: ScinoPharm (Tainan) is an established peptide and small-molecule CDMO. It has a multi-decade record supplying innovator and generic drug programmes, and states kilogram-scale GMP peptide capability plus FDA/PMDA inspection history.

Every GMP, FDA-registration, and certification claim above is company-stated. If you are doing due diligence, request certificates directly and check regulatory database listings yourself.

BIOSECURE update (as of mid-2026): The BIOSECURE Act was signed into law on December 18, 2025 as part of the FY2026 National Defense Authorization Act. Earlier drafts named specific firms; the enacted version does not name WuXi AppTec (or WuXi Biologics, BGI, MGI, Complete Genomics) as "biotechnology companies of concern." Separately, the U.S. Department of Defense added WuXi AppTec to its Section 1260H list of "Chinese military companies" on June 8, 2026 (Federal Register notice June 10, 2026), a designation WuXi has said it will contest. Legal analysts read the 1260H listing as a pathway to company-of-concern status, but any BIOSECURE prohibitions would take effect only after further regulatory steps and grandfathering periods, potentially years out. Sources: Ropes \u0026 Gray, FDA Law Blog.

How API becomes research product

Finished research peptides go through several steps after API synthesis: lyophilisation, vial filling, labelling, and fulfilment. Many research vendors source API from one or more of the manufacturers above, then handle finishing in-house or through a third party. So a vendor's quality only partly traces back to the upstream API source. Handling, reconstitution, storage, and labelling accuracy each add their own variables.

Independent testing services

Vendor-published COAs are self-reported, so a set of third-party testing and aggregation services has grown up around them. Their models differ in substance.

Finnrick (finnrick.com) buys peptide samples itself, ships them to commercial laboratories, and publishes per-vendor A–E safety grades broken down by individual peptide. The grades sit on a per-sample 0–10 score that combines purity, label/quantity accuracy, and batch-information quality. As of mid-2026 its homepage reports roughly 8,000+ tests across 225+ vendors. Finnrick commissions and owns the testing rather than curating documents the vendor supplies.

VialAudit (vialaudit.com) runs as an independent audit desk. It places anonymous blind-buy orders and routes them to rotating, vendor-blind third-party laboratories. It publishes a 0–100 composite audit score, weighting purity (40%), label accuracy (25%), shipping (20%), and service (15%), as a vendor leaderboard, alongside a COA archive, pricing index, and a public corrections log.

Peptigrity (peptigrity.com) aggregates individual per-test HPLC records. Each one is attributed to the laboratory that actually ran it (Janoshik, Vanguard, Freedom Diagnostics, MZ Biolabs, and others), along with peptide name, vendor, purity percentage, and date. Its stated position: "we don't sell peptides, we verify them."

PeptideBenchmark (peptidebenchmark.com) is a meta-aggregator. It normalises Finnrick's test data and Peptide Critic's community ratings into a single 0–10 benchmark score with confidence/transparency tiers across roughly 280+ tracked vendors. Because it re-blends Finnrick data, it is not independent of Finnrick.

The peptideone Score (0–10) draws on the three genuinely independent signals: Finnrick (weighted 0.45), VialAudit (0.30), and Peptigrity HPLC purity (0.25). PeptideBenchmark is left out to avoid double-counting Finnrick's underlying test data.

What this means for research buyers

Asian API capacity is what makes global research-peptide supply possible at current prices. By itself it says nothing about the quality of any finished product. The most reliable external signal of what is actually in a vial comes from the third-party testing services, each running a different methodology. Cross-referencing Finnrick grades, VialAudit composite scores, and Peptigrity HPLC records gives a fuller picture than any single source. These remain research-use-only materials, not products approved for human use.

Sources

• finnrick.com
• vialaudit.com
• peptigrity.com
• peptidebenchmark.com
• hybio.com
• sinopep.com
• wuxiapptec.com
• enogen.com.cn
• anygen.co.kr
• scinopharm.com
• janoshik.com
• ropesgray.com
• thefdalawblog.com
• fda.gov
• pubmed.ncbi.nlm.nih.gov